Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial

Rajesh Thomas, Edward T.H. Fysh, Nicola A. Smith, Pyng Lee, Benjamin C.H. Kwan, Elaine Yap, Fiona C. Horwood, Francesco Piccolo, David C.L. Lam, Luke A. Garske, Ranjan Shrestha, Christopher Kosky, Catherine A. Read, Kevin Murray, Y. C.Gary Lee

Research output: Contribution to journalArticle

99 Citations (Scopus)
476 Downloads (Pure)

Abstract

IMPORTANCE: Indwelling pleural catheter and talc pleurodesis are established treatments for malignant pleural effusions among patients with poor prognosis. OBJECTIVE: To determine whether indwelling pleural catheters are more effective than talc pleurodesis in reducing total hospitalization days in the remaining lifespan of patients with malignant pleural effusion. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized clinical trial included participants recruited from 9 centers in Australia, New Zealand, Singapore, and Hong Kong between July 2012 and October 2014; they were followed up for 12 months (study end date: October 16, 2015). Patients (n = 146) with symptomatic malignant pleural effusion who had not undergone indwelling pleural catheter or pleurodesis treatment were included. INTERVENTIONS: Participants were randomized (1:1) to indwelling pleural catheter (n = 74) or talc pleurodesis (n = 72), minimized by malignancy (mesothelioma vs others) and trapped lung (vs not), and stratified by region (Australia vs Asia). MAIN OUTCOMES AND MEASURES: The primary end point was the total number of days spent in hospital from procedure to death or to 12 months. Secondary outcomes included further pleural interventions, patient-reported breathlessness, quality-of-life measures, and adverse events. RESULTS: Among 146 randomized patients (median age, 70.5 years; 56.2% male), 2 were excluded. The indwelling pleural catheter group spent significantly fewer days in hospital than the pleurodesis group. The reduction was mainly in effusion-related hospitalization days. Fewer patients randomized to indwelling pleural catheter required further ipsilateral invasive pleural drainages. There were no significant between-group differences in improvements in breathlessness or quality of life. Adverse events occurred in both groups: 30 events in 22 catheter patients and 23 events in 13 talc pleurodesis patients. (Table Presented). CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, treatment with an indwelling pleural catheter vs talc pleurodesis resulted in fewer hospitalization days from treatment to death, but the magnitude of the difference is of uncertain clinical importance. These findings may help inform patient choice of management for pleural effusion. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000567921.

Original languageEnglish
Pages (from-to)1903-1912
Number of pages10
JournalJAMA - Journal of the American Medical Association
Volume318
Issue number19
DOIs
Publication statusPublished - 21 Nov 2017

Fingerprint Dive into the research topics of 'Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial'. Together they form a unique fingerprint.

Cite this